Table 1. Clinicopathological characteristics of 75 HBV-related HCC patients.
| Characteristics | No. of Patients | Median (Range) |
|---|---|---|
| Age (years) | 75 | 53 (26–78) |
| >50 | 48 | 60 (51–78) |
| ≤50 | 27 | 43 (26–50) |
| Gender (men/women) | 68/7 | |
| Smoking (yes/no) | 31/44 | |
| Alcohol (yes/no) | 29/46 | |
| HBsAg (positive/negative/NA) | 65/0/10 | |
| HBeAg (positive/negative/NA) | 9/62/4 | |
| HBV genotype (B/C) | 60/15 | |
| HBV DNA (copies/mL) (20–1.7×108/<20)a | 74/1 | 2.1×104 (21.5–1.5×108)c |
| >1×104 | 42 | 4.3×105 (1.2×104−1.5×108) |
| ≤1×104 | 32 | 8.4×102 (21.5–9.3×103) |
| Albumin (g/dL) | 75 | 3.7 (1.2–4.9) |
| >3.8 | 30 | 4.2 (3.9–4.9) |
| ≤3.8 | 45 | 3.3 (1.2–3.8) |
| AST (U/L) | 75 | 60 (14–1052) |
| >34 | 61 | 79 (35–1052) |
| ≤34 | 14 | 27 (14–34) |
| ALT (U/L) | 75 | 55 (13–1338) |
| >40 | 50 | 96.5 (41–1338) |
| ≤40 | 25 | 31 (13–40) |
| AFP (ng/mL) (≤54000/>54000)b | 71/4 | 26.7 (1.8–36600.0)d |
| >400 | 28 | 1920 (461.7–36600.0) |
| ≤400 | 47 | 13.8 (1.8–271.0) |
| Tumor size (cm) | 75 | 4.5 (1.1–19.5) |
| >5 | 37 | 10.0 (5.5–19.5) |
| ≤5 | 38 | 2.4 (1.1–4.5) |
| Tumor encapsulation (yes/no/NA) | 42/20/13 | |
| Lymph node involvement (yes/no) | Aug-67 | |
| Portal vein thrombosis (yes/no) | May-70 | |
| Vascular invasion (yes/no) | 27/48 | |
| Distant metastasis (yes/no) | Aug-67 | |
| Steatosis grade (0/1/2/3/NA) | 14/10/1/0/50 | |
| Metavir inflammation score (0/1/2/3/NA) | 4/35/5/0/31 | |
| Ishak fibrosis score (0/1/2/3/4/5/6/NA) | 5/13/12/8/3/4/11/19 | |
| Child-Pugh cirrhosis score (A/B/C) | 57/16/2 | |
| CLIP score (0/1/2/3/4/5/6) | 33/23/10/8/1/0/0 | |
| BCLC stage (A/B/C/D) | 38/29/7/1 | |
| AJCC TNM stage (I/II/IIIA/IIIB/IIIC/IVA/IVB) | 40/20/7/5/3/0/0 | |
| Antiviral therapy after surgery (yes/no) | 40/35 | |
| HCC recurrence after surgery (month) (yes/no) | 52/23 | 11.2 (1.5–72.3)e |
| Survival after surgery (month) (dead/alive) | 16/59 | 26.9 (6.8–161.1)f |
aHBV DNA was measured with a detection range of 20 to 1.7×108 copies/mL.
bAFP was measured with the highest detection limit of 54000 ng/mL.
c,dOnly data within the detection range were analyzed.
eShown was the time to recurrence after surgery.
fShown was survival time in patients who died after surgery.
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HBeAg, hepatitis B e antigen; NA, not available; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; CLIP, Cancer of the Liver Italian Program; BCLC, Barcelona Clinic Liver Cancer; AJCC, American Joint Committee on Cancer; TNM, tumor-node-metastasis.